1 min read
Medicenna Posts $0.04 Q2 Loss Per Share as Cash Falls to $3.7 Million
Cash and cash equivalents were $5.7 million on June 30, 2026.

Medicenna Therapeutics Corp. ended the second quarter of fiscal 2027 with $3.7 million in cash and cash equivalents. Medicenna said it does not have enough cash to support its planned operations for the coming year and will need to raise more funding.
The cash balance on Sept. 30, 2026, was down from $5.7 million on June 30, 2026.
Medicenna posted a loss of $0.04 per share for the quarter, which ended Sept. 30.